Citations

Showing 10 of 108162 citations.

Using Dual-Energy CT to Identify Small Foci of Hemorrhage in the Emergency Setting
Kotsenas, Amy L. , Halaweish, Ahmed F

Mayo Clinic

Radiology | November 5, 2019 | Volume: 294 | Issue: 1 | Pages: 139-140

10.1148/radiol.2019192258 | PMID 31689156 Get It

Anesthetic management of lung transplantation: impact of presenting disease
Fritz, Ashley Virginia , Wilkey, Barbara , Martin, Archer Kilbourne , Fritz, Ashley V

Mayo Clinic

Current Opinion in Anaesthesiology | November 5, 2019 | Volume: 33 | Issue: 1 | Pages: 43-49

10.1097/aco.0000000000000805 | PMID 31688086 Get It

Purpose of reviewRecent literature has described the emerging role of anesthesiologists as key members of the lung transplantation team and the impact of anesthetic management on outcomes. This review examines the impact of presenting cause of end-stage lung disease (ESLD) on anesthetic management.Recent findingsThe four primary causes of ESLD are suppurative, obstructive, or restrictive processes, and pulmonary hypertension. Our recent review of perioperative literature revealed new data regarding preoperative risk stratification, intraoperative management, and postoperative use of extracorporeal membrane oxygenation (ECMO) support. Major studies specifically about anesthetic management are lacking; however, the principles studied are readily applicable to the design of a perioperative care plan. The most compelling data have resulted in a revolutionary change in terms of intraoperative support and postoperative planning for pulmonary hypertension patients. Historically treated with cardiopulmonary bypass, significant data have been reported describing the successful use of ECMO both as an intraoperative support with superior outcomes, as well as postoperative support for improved stability during biventricular remodeling post graft implantation.SummaryThe application of these updated findings should assist anesthesiologists as they develop internal protocols and external guidelines to integrate within multidisciplinary teams caring for the lung transplant patient.
Elevating Evidence-Based Practice: A Multi-Site Workshop Pilot for Nurses
Almader‐Douglas, Diana , Brigham, Tara , Marks, Lisa , Jett, Heather , Brigham, T J , Marks, Lisa A

Mayo Clinic

Medical Reference Services Quarterly | November 5, 2019 | Volume: 38 | Issue: 4 | Pages: 387-401

10.1080/02763869.2019.1657737 | PMID 31687910 Get It

Using Contingent Medical Librarians to Address Workforce Staffing Dilemmas
Morgan, Anna Beth

Mayo Clinic

Medical Reference Services Quarterly | November 5, 2019 | Volume: 38 | Issue: 4 | Pages: 376-386

10.1080/02763869.2019.1657732 | PMID 31687906 Get It

Representation of Women Among Invited Speakers at Medical Specialty Conferences
Sharkey, Katherine M. , Poorman, Julie A., Kan, Carolyn , Moeschler, Susan M. , Chandrabose, Rekha K. , Marquez, Carol, Dodge, Daleela , Nazarian, Rosalynn M. , Larson, Allison R , Silver, Julie K.

Mayo Clinic

Journal of Women's Health | November 5, 2019 | Volume: 29 | Issue: 4 | Pages: 550-560

10.1089/jwh.2019.7723 | PMID 31687866 Get It

Androgen Therapy in Women
Vegunta, Suneela , Kling, Juliana M. , Kapoor, Ekta , Kling, Juliana M

Mayo Clinic

Journal of Women's Health | November 5, 2019 | Volume: 29 | Issue: 1 | Pages: 57-64

10.1089/jwh.2018.7494 | PMID 31687883 Get It

Androgens are believed to have an important biologic role in women, particularly in regulation of libido and sexual arousal, although much about their function on other systems in women is unknown. Testosterone, the primary ovarian androgen, has been used to treat carefully selected postmenopausal women with hypoactive sexual desire disorder (HSDD). However, testosterone use in women has not been approved by the United States Food and Drug Administration (FDA) because of uncertainties regarding the effectiveness and long-term safety of this strategy. An intravaginal form of the adrenal androgen, dehydroepiandrosterone (DHEA) has been approved by the FDA to treat genitourinary syndrome of menopause. In this article, we review the current knowledge regarding the role of androgens and their clinical use in women. We conducted a systematic search of PubMed for publications describing the role and clinical use of androgens in women. We used the search terms “HSDD,” “DHEA in women,” “testosterone in women,” and “androgens in women,” and reviewed most references from all relevant articles. Most randomized placebo-controlled trials show an improvement in sexual function with low-dose testosterone therapy in select postmenopausal women with HSDD. Although this strategy appears to be safe in the short term and no major safety concerns have emerged thus far, long-term effects on cardiovascular risk and breast cancer incidence are not known. A trial of low-dose testosterone therapy may be considered for carefully selected postmenopausal women with HSDD, as long as other contributors to sexual dysfunction have been adequately addressed. However, patients need careful counseling regarding the lack of long-term safety data, and close clinical and laboratory monitoring of these women is recommended to avoid supraphysiologic dosing.
Influence of Guidelines in Endovascular Therapy Decision Making in Acute Ischemic Stroke
Kashani, Nima , Menon, Bijoy K. , Saposnik, Gustavo , Sylaja, Pillai N., Heo, Ji Hoe , Mitchell, Peter , Cherian, Mathew , Turjman, Francis , Kim, Byung Moon , Fischer, Urs , Wilson, Alexis , Baxter, Blaise, Hill, Michael D. , Hill, Michael D , Fischer, Urs , Ospel, Johanna M. , Almekhlafi, Mohammed , Campbell, Bruce , Rabinstein, Alejandro A. , Yoshimura, Shinichi , Goyal, Mayank

Mayo Clinic

Stroke | November 5, 2019 | Volume: 50 | Issue: 12 | Pages: 3578-3584

10.1161/strokeaha.119.026982 | PMID 31684847 Get It

Background and Purpose— The American Heart Association and the American Stroke Association guidelines for early management of patients with ischemic stroke offer guidance to physicians involved in acute stroke care and clarify endovascular treatment indications. The purpose of this study was to assess concordance of physicians’ endovascular treatment decision-making with current American Heart Association and the American Stroke Association stroke treatment guidelines using a survey-approach and to explore how decision-making in the absence of guideline recommendations is approached. Methods— In an international cross-sectional survey (UNMASK-EVT), physicians were randomly assigned 10 of 22 case scenarios (8 constructed with level 1A and 11 with level 2B evidence for endovascular treatment and 3 scenarios without guideline coverage) and asked to declare their treatment approach (1) under their current local resources and (2) assuming there were no external constraints. The proportion of physicians offering endovascular therapy (EVT) was calculated. Subgroup analysis was performed for different specialties, geographic regions, with regard to physicians’ age, endovascular, and general stroke treatment experience. Results— When facing level 1A evidence, participants decided in favor of EVT in 86.8% under current local resources and in 90.6% under assumed ideal conditions, that is, 9.4% decided against EVT even under assumed ideal conditions. In case scenarios with level 2B evidence, 66.3% decided to proceed with EVT under current local resources and 69.7% under assumed ideal conditions. Conclusions— There is potential for improving thinking around the decision to offer endovascular treatment, since physicians did not offer EVT even under assumed ideal conditions in 9.4% despite facing level 1A evidence. A majority of physicians would offer EVT even for level 2B evidence cases.
Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells
Anderson, George , Rodriguez, Moses , Rodriguez, Moses , Reiter, Russel Joseph

Mayo Clinic

International Journal of Molecular Sciences | November 5, 2019 | Volume: 20 | Issue: 21 | Pages: 5500

10.3390/ijms20215500 | PMID 31694154 Get It

Recent data highlight the important roles of the gut microbiome, gut permeability, and alterations in mitochondria functioning in the pathophysiology of multiple sclerosis (MS). This article reviews such data, indicating two important aspects of alterations in the gut in the modulation of mitochondria: (1) Gut permeability increases toll-like receptor (TLR) activators, viz circulating lipopolysaccharide (LPS), and exosomal high-mobility group box (HMGB)1. LPS and HMGB1 increase inducible nitric oxide synthase and superoxide, leading to peroxynitrite-driven acidic sphingomyelinase and ceramide. Ceramide is a major driver of MS pathophysiology via its impacts on glia mitochondria functioning; (2) Gut dysbiosis lowers production of the short-chain fatty acid, butyrate. Butyrate is a significant positive regulator of mitochondrial function, as well as suppressing the levels and effects of ceramide. Ceramide acts to suppress the circadian optimizers of mitochondria functioning, viz daytime orexin and night-time melatonin. Orexin, melatonin, and butyrate increase mitochondria oxidative phosphorylation partly via the disinhibition of the pyruvate dehydrogenase complex, leading to an increase in acetyl-coenzyme A (CoA). Acetyl-CoA is a necessary co-substrate for activation of the mitochondria melatonergic pathway, allowing melatonin to optimize mitochondrial function. Data would indicate that gut-driven alterations in ceramide and mitochondrial function, particularly in glia and immune cells, underpin MS pathophysiology. Aryl hydrocarbon receptor (AhR) activators, such as stress-induced kynurenine and air pollutants, may interact with the mitochondrial melatonergic pathway via AhR-induced cytochrome P450 (CYP)1b1, which backward converts melatonin to N-acetylserotonin (NAS). The loss of mitochnodria melatonin coupled with increased NAS has implications for altered mitochondrial function in many cell types that are relevant to MS pathophysiology. NAS is increased in secondary progressive MS, indicating a role for changes in the mitochondria melatonergic pathway in the progression of MS symptomatology. This provides a framework for the integration of diverse bodies of data on MS pathophysiology, with a number of readily applicable treatment interventions, including the utilization of sodium butyrate.
Autologous Breast Reconstruction after Failed Implant-Based Reconstruction: Evaluation of Surgical and Patient-Reported Outcomes and Quality of Life
Oliver, Jeremie D. , Myckatyn, Terence M. , Oliver, Jeremie D , Tenenbaum, Marissa M.

Mayo Clinic

Plastic & Reconstructive Surgery | November 4, 2019 | Volume: 144 | Issue: 5 | Pages: 931e-932e

10.1097/prs.0000000000006111 | PMID 31688775 Get It

A Cross-Sectional Analysis of Migraine-Related Disability in CADASIL
Badi, Mohammed K. , Klaas, James P. , Glover, Patrick , Rozen, Todd D. , Huang, Josephine F. , Goldstein, Eric D , Lin, Michelle P, Badi, Mohammed , Goldstein, Eric , Lin, Michelle , Meschia, James F.

Mayo Clinic

The Neurologist | November 4, 2019 | Volume: 24 | Issue: 6 | Pages: 161-164

10.1097/nrl.0000000000000253 | PMID 31688705 Get It

Objectives: Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is inherited microangiopathy characterized by recurrent subcortical infarcts. A majority of those with CADASIL report coexistent migraine with aura. The authors aim to quantitatively describe migraine-related disability within a CADASIL cohort. Methods: A cross-sectional analysis was performed in a cohort of CADASIL. The Migraine Disability Assessment (MIDAS) quantified migraine-related disability. Further metrics obtained include first and last migraine, aura semiology, and therapeutic measures. Results: Twenty-four individuals were included [63% (15/24) female individuals; mean age, 56 y; range, 34 to 81 y]. Fifty-four percent (13/24) reported migraine, whereas 46% (11/24) reporting varying degrees of migraine-related disability. MIDAS Questionnaire scores appeared bimodal: 58% (14/24) scored 0 to 5, 7% (1/24) scored 6 to 10, 7% (1/24) scored 11 to 20 and 33% (8/24) scored over 20. Severe disability was associated with the multiplicity of aura semiologies and poor response to pharmacologic prophylaxis. Conclusions: A bimodal distribution of migraine-related disability was observed. A third of individuals had a severe disability and appeared medically refractory to medical migraine prophylactic measures. This study may serve as a reference point for future trials quantitatively gauging response of novel migraine treatment strategies within this unique population.